Caraway Therapeutics appoint industry veteran as CEO

Caraway Therapeutics, an emerging biopharma based in Cambridge, MA, has expanded its leadership team with the addition of industry veteran Martin D Williams as CEO.

Mr Williams brings more than three decades of global biopharma experience to Caraway, including public and venture-backed biotechnology firms and multinational pharmaceutical companies.

He was most recently Executive Chairman of Yuma Therapeutics, a company focused on neurodegenerative conditions which he co-founded. He will remain on Yuma’s board of directors.

Previously, he held a series of leadership roles at pharmaceutical companies, including President and CEO of Tokai Pharmaceuticals, and Chief Business Officer of Dicerna Pharmaceuticals and Synta Pharmaceuticals.

Caraway Therapeutics is pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons.

“Neurodegenerative diseases are among the greatest unmet medical and public health needs.  Caraway’s rigorous scientific approach supported by human genetic data, renowned co-founders and dedication to developing treatments for patients compelled me to join the company,” said Mr. Williams.

“I look forward to working with the team to continue advancing our science toward the clinic for the benefit of patients suffering from these devastating diseases.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news